RedHill Biopharma Ltd.'s RHB-104 Combination Achieves 80% Remission in Independent Pediatric Crohn's Study
Published: Oct 15, 2013
TEL-AVIV, Israel, Oct. 15, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations and combinations of existing drugs, reported the presentation of a poster at the ACG (American College of Gastroenterology) 2013 Annual Scientific Meeting on October 14, 2013, and the pending publication in the American Journal of Gastroenterology, of positive results from an independent, single-center, retrospective study with 10 pediatric patients suffering from Crohn's disease - an inflammatory disease of the gastrointestinal system with significant unmet medical need. The patients were treated with an earlier formulation of RedHill's RHB-104 anti-MAP (Mycobacterium avium subspecies paratuberculosis) combination therapy, using the same active ingredients in doses adjusted for pediatric usage.
Help employers find you! Check out all the jobs and post your resume.